TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence
NCT ID: NCT00463554
Last Updated: 2023-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
72 participants
OBSERVATIONAL
2006-04-01
2007-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TVT-SECUR as an Office-based Procedure
NCT01137539
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
NCT04829357
Post-Market Clinical Follow-Up onTVT EXACT® Continence System
NCT04829994
Study Comparing TVT With TVT-SECUR for the Treatment of Stress Urinary Incontinence
NCT00534365
GTx-024 as a Treatment for Stress Urinary Incontinence in Women
NCT02658448
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GYNECARE TVT-SECUR* System
A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be at least 21 years old.
* Must be postmenopausal (amenorrhea) for at least 1 year or surgically sterile (bilateral salpingo-oophorectomy or tubal ligation or otherwise be incapable of pregnancy) or has a negative pregnancy test prior to study entry and has decided to cease childbearing.
* Agrees to participate in the study, including all study related procedures and evaluations and documents this agreement by signing the IRB/EC-approved informed consent
Exclusion Criteria
* Have intrinsic sphincter deficiency (ISD) \[Urethral Pressure Profile (UPP) with a maximum urethral closing pressure (MUCP) \< 20cm H2O or Leak Point Pressure (LPP) \< 60\].
* Have an active urinary tract infection (UTI) or vaginal infection at time of surgery.
* Have a fixed urethra (\< 30° mobility on Q-Tip Straining Test).
* Have had prior incontinence surgery.
* Have a post-void residual volume \> 100mL.
* Have co-existent pelvic organ prolapse that is symptomatic or extends beyond the hymen.
* Have lower urinary tract pathology in the form of a fistula or diverticulum.
* Have a malignancy or with a history of malignancy within the past 5 years, except for a basal cell carcinoma that has been treated with local excision and is no longer present.
* Are on anticoagulant therapy.
* Have received an experimental drug or used an experimental medical device within 30 days prior to the planned start of treatment.
* Are deemed by the investigator as medically unfit for surgery or who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings or contraindications outlined in the GYNECARE TVT SECUR System IFU.
* Employees of the investigator or study center with direct involvement in the proposed study or other studies under the direction of that investigator or study center.
21 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ethicon, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Robinson, MD
Role: STUDY_DIRECTOR
Ethicon, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Michigan Institute of Women's Health
Dearborn, Michigan, United States
Good Samaritan Hospital
Cincinnati, Ohio, United States
The Institute for Female Pelvic Medicine and Reconstructive Surgery
Allentown, Pennsylvania, United States
Vanderbilt University
Nashville, Tennessee, United States
Helsinki University Central Hospital
Helsinki, , Finland
University of Padova
Padua, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
300-05-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.